Skip to main content

Table 1 Overview of the schizophrenia patient population

From: The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia

 

LAI New User

LAI Continuous User

LAI Total

Oral APT

Other Injectable/Unknown

Study Total

 

n = 235

n = 385

n = 620

n = 377

n = 68

N = 1065

Schizophrenia

 Baseline

214

385

599

281

64

944

 Month 6

173 (80.8)

326 (84.7)

499 (83.3)

230 (81.9)

40 (62.5)

769 (81.5)

 Month 12

156 (72.9)

290 (75.3)

446 (74.5)

204 (72.6)

32 (50.0)

682 (72.2)

  1. APT antipsychotic therapy, LAI long-acting injectable, NA not applicable
  2. Among the 599 patients with schizophrenia in the total LAI group, 482 were receiving PP LAI (174 new users; 308 continuous users) and 117 were receiving RLAI (40 new users; 77 continuous users)
  3. Values in parentheses are percentages unless otherwise specified
  4. New user was defined as a study patient who initiated PP LAI or RLAI treatment within 8 weeks (≤56 days) of the enrollment period
  5. Continuous user was defined as a study patient who initiated PP LAI or RLAI treatment more than 8 weeks (>56 days) after the enrollment visit